Anavex Life Sciences Corp.(www.anavex.com) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases.
Anavex is currently in a Phase 2a trial for Alzheimer's disease (AD) with lead therapeutic, ANAVEX 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the Sigma-1 Receptor. PART A topline data of our ongoing Phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. ANAVEX 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: Rett syndrome, as well is in epilepsy and multiple sclerosis (MS). In 2015, the Company was awarded a research by the Michael J. Fox Foundation (MJFF) to study ANAVEX 2-73 for the treatment of Parkinson’s disease.
Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.
Location: United States, New York
Employees: 11-50
Phone: +1 844-689-3939
Founded date: 2006
Investors 1
| Date | Name | Website |
| - | SymBiosis | symbiosis.... |
Mentions in press and media 14
| Date | Title | Description | Source |
| 13.03.2024 | AVXL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP An... | - | globenewsw... |
| 04.03.2024 | Anavex Life Sciences Investigated by Block & Leviton For... | BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences... | einpresswi... |
| 29.06.2023 | Roundups: 22 Recent Strategic Digital Health Partnerships | Advantus Health Partners forms a new 10-year, $2.9B strategic partnership with Medline to establish ... | hitconsult... |
| 21.07.2022 | 180 Life Sciences Corp. Announces Closing of $6.5 Million Re... | PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Lif... | globenewsw... |
| 18.07.2022 | 180 Life Sciences Corp. Announces $6.5 Million Registered Di... | PALO ALTO, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Lif... | globenewsw... |
| 02.02.2022 | A win in Rett syndrome? Not so fast — biotech shares slide ... | Normally, an announcement that a Phase III trial met all primary and secondary efficacy a... | endpts.com... |
| 12.08.2021 | Anavex Life Sciences Provides Business Update and Reports Fi... | Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesi... | marketscre... |
| 29.07.2021 | Anavex Life Sciences : Announces ANAVEX®2-73 (Blarcamesine) ... | Pre-Treatment with ANAVEX®2-73 entirely prevented Abeta-induced cognitive decline Anavex planning a ... | marketscre... |
| 24.06.2021 | Anavex Life Sciences Announces Closing of $50 Million Regist... | NEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (... | marketscre... |
| 22.06.2021 | Anavex Life Sciences : Announces $50 Million Registered Dire... | NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (... | marketscre... |
Show more